EUCTR2016-002780-34-BE进行中（未招募）1 期
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone DeficiencyThe VISTA Study: Versartis Long-Term Safety Study of Somavaratan
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria for Subjects Completing a Previous Somavaratan Study:
- •1.Completion of a somavaratan clinical study in pediatric subjects with GHD.
- •2.Willing and able to comply with all study procedures.
- •Inclusion Criteria for New Treatment Naïve Subjects:
- •1.Chronological Age = 3.0 years.
- •2.Pre-pubertal status: Absent breast development in girls, testicular volume < 4.0 mL in boys.
- •3.Diagnosis of GHD as documented by two or more GH stimulation test results = 10.0 ng/mL. The use of prior GH stimulation test results is permitted providing the stimulatory agents, GH assay and test results are approved in writing by the Medical Monitor. In localities with different diagnostic criteria, any child meeting the GH stimulation test criteria described here will be considered eligible.
- •4.Normal thyroid function at Screening Visit in subjects not being treated for hypothyroidism. Subjects requiring thyroxine replacement must be considered adequately treated by the PI and Medical Monitor.
- •5.Normal adrenal function (morning cortisol and/or local stimulation test) at Screening Visit or within 6 months of the Screening Visit, in subjects not being treated for adrenal insufficiency. Subjects with adrenal insufficiency must receive glucocorticoid treatment for a minimum of 4 weeks before study drug administration.
- •6.Pathology relating to cause of GHD must be stable for at least 6 months prior to screening.
- •7.Legally authorized representatives must be willing and able to give informed consent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 300
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria for Subjects Completing a Previous Somavaratan Study:
- •1.Withdrawal from a somavaratan clinical study in pediatric subjects with GHD.
- •2.Use of certain medications with potential to alter responses to the test product including, but not limited to, IGF-I, GH-releasing hormone, and chronic anti-inflammatory doses of glucocorticoids.
- •3.Presence of a significant medical condition if such a condition or its treatment can influence the response to study drug (e.g., diabetes, renal failure).
- •Exclusion Criteria for New Treatment Naïve Subjects:
- •1.Prior/concomitant treatment with any growth promoting agent (e.g., GH, IGF-I, GH releasing hormone (GHRH), gonadotrophins, sex steroids). Up to 10 day exposures to a growth promoting agent for diagnostic purposes are permitted if administered 30 or more days prior to screening.
- •2.Current, significant disease (e.g., diabetes, cystic fibrosis, renal insufficiency). In all cases of concurrent disease, screening must be approved in writing by the Medical Monitor.
- •3.Chromosomal aneuploidy, significant gene mutations (other than those that cause GHD) or confirmed diagnosis of a named syndrome (e.g., Russell Silver, Prader Willi, Turner, etc.). Unconfirmed or suspected genetic variants will be considered individually.
- •4.Birth weight and/or birth length less than 5th percentile for gestational age using gestational age growth charts.
- •5.Prolonged daily (>14 days) use of anti-inflammatory doses of oral glucocorticoids.
- •6.Prior history of malignancy.
- •7.Treatment with an investigational drug in the 30 days prior to screening.
- •8.Known allergy to constituents of the study drug formulation.
- •9.Ocular findings suggestive of increased intracranial pressure and/or retinopathy at screening.
- •10.Significant spinal abnormalities including scoliosis, kyphosis, Chiari malformation, and spina bifida variants.
- •11.Significant abnormality in screening studies (as assessed by PI and Medical Monitor).
- •12.Current social conditions which would prevent completion of study activities (e.g., planned family move to a distant location).
- •13.History of pancreatitis or undiagnosed chronic abdominal pain.
- •14.History of spinal or total body irradiation.
- •15.Other pituitary hormone deficiencies that are not properly treated.
- •16.Unwillingness to provide consent for participation in all trial activities.
研究者
相似试验
进行中（未招募）
1 期
A Long-Acting Growth Hormone (Somavaratan, VRS-317) in ChildreEUCTR2016-002780-34-SEVersartis, Inc.400
进行中（未招募）
1 期
A Long-Acting Growth Hormone (Somavaratan, VRS-317) in ChildreGrowth hormone deficiencyMedDRA version: 20.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersEUCTR2016-002780-34-PLVersartis, Inc.400
进行中（未招募）
1 期
A clinical study in children and adolescents with Tourette Syndrome to investigate the safety of TEV-50717 (experimental drug).Tics associated with Tourette Syndrome(TS)EUCTR2016-000630-22-ROTeva Branded Pharmaceutical Products R&D, Inc.228
进行中（未招募）
1 期
A clinical study in children and adolescents with Tourette Syndrome to investigate the safety of TEV-50717 (experimental drug).Tics associated with Tourette Syndrome(TS)EUCTR2016-000630-22-ESTeva Branded Pharmaceutical Products R&D, Inc.260
进行中（未招募）
1 期
A clinical study in children and adolescents with Tourette Syndrome to investigate the safety of TEV-50717 (experimental drug).Tics associated with Tourette Syndrome(TS)EUCTR2016-000630-22-SETeva Branded Pharmaceutical Products R&D, Inc.260